Scribe Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · +0.44%
- Market cap
- $321.46M
- 18.94M shares
- Filings
- 48
Q3 2026
—Q3 2026
—Q3 2026
—Q3 2026derived
—Q3 2026
—Q3 2026−3.6% FY25 yoy
- $321.46M
- —
- —
- 2.6×
- —
- —
FY2026 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
No annual history for this metric yet.
| Period | Ended | Value | Kind | Source trail |
|---|
Biological products, except diagnostic substances
Scribe Therapeutics, Inc. is the 76th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
PROKProkidney Corp.$893.0K1,075.0%7,725.2%$347.7MEDITEditas Medicine, Inc.$40.5M25.4%395.0%$329.5MEIKNEikon Therapeutics, Inc.———$327.8MXFORX4 Pharmaceuticals, Inc$35.1M1,273.2%225.6%$324.2MAGENAgenus Inc$114.2M10.4%2.7%$323.1M
SCTXScribe Therapeutics, Inc. (this company)———$321.5M
AUTLAutolus Therapeutics plc$75.4M644.9%381.4%$318.3MKYTXKyverna Therapeutics, Inc.———$317.4MOCGNOcugen, Inc.$4.4M8.8%1,537.4%$296.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Scribe Therapeutics, Inc. · CIK 1853921 · Engraved from SEC EDGAR